Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Fig. 2

ANK2 mutation frequency across cancers and survival analysis of LUAD based on ANK2 mutation status. A: The prevalence of ANK2 mutation across 30 types of cancers. B: Lollipop plot shows the distribution of ANK2 mutation in LUAD. C: Overall survival (OS) analysis stratified by ANK2 mutation status in LUAD from cBioportal. D: Progress-free survival (PFS) analysis stratified by ANK2 mutation status in LUAD from cBioportal. E: Disease-specific survival (DSS) analysis stratified by ANK2 mutation status in LUAD from cBioportal

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us